IV. 6 Prevention: antibiotic stewardship and the environment

Holding on to your recovery depends on prevention. In this chapter you will learn the most important preventive tools – from conscious antibiotic use through environmental hygiene to lifestyle – so that you can keep the chance of relapse low for years to come.

Antibiotic stewardship: your most important line of defence

If there is a single thing to remember about prevention, it is this: the antibiotic is the greatest disruptor of your gut flora^[G], and it is precisely this that opens the way for C. difficile to return. Antibiotics do not discriminate – while they destroy the targeted bacterium, they also decimate the useful, protective flora, and the emptied "space" can easily be taken over by the pathogen. This does not mean you must never take an antibiotic again; there are situations where it is life-saving. The key is awareness: only when it is truly justified, and always in such a way that your treating physician knows your CDI history.

In practice this means a few simple rules. Never take an antibiotic on your own initiative or from leftovers; always ask whether it is genuinely needed, and whether there is a narrower-spectrum or safer alternative. If another doctor (for example a dentist or emergency care) prescribes an antibiotic, always mention that you have had recurrent C. difficile infection – this information can influence the choice. This kind of conscious antibiotic use is the backbone of prevention.

And there is an important connection to the course of treatment as well: if in future you do need an antibiotic and would meanwhile start a DiffBiome course, the antibiotic must always be finished before the live flora is delivered, with an appropriate interval – otherwise the antibiotic would also destroy the freshly delivered bacteria. Always discuss this with your doctor.

The antibiotic is not the only medication that affects your flora. From time to time it is worth reviewing your chronically taken medications with your doctor as well. Among acid suppressants, proton pump inhibitors^[G] (PPIs) – which many people take for years, often unnecessarily by now – reduce the protective acidity of the stomach and raise the risk of CDI. You should not stop them arbitrarily, but it is worth asking the question: "is this still necessary?". It is similarly worth reviewing agents that slow gut motility (anticholinergic, opioid-type drugs), because the pathogen multiplies more easily in a sluggish gut. The point is not self-diagnosis, but a regular, joint medication review with your doctor – every unnecessary drug that can be dropped is one more layer of protection for your flora.

The environment and lifestyle: the quiet safety net

Alongside antibiotic stewardship, environmental hygiene is the second pillar of prevention. C. difficile spreads through resistant spores^[G], which the usual hand sanitiser does not always destroy reliably – so frequent, thorough handwashing with soap and water is the most effective protection, especially after using the toilet and before eating. In the household, regular cleaning of frequently touched surfaces (toilet, door handles, taps) also reduces the presence of spores. This is not excessive worry, but a simple, quiet safety net in everyday life.

Environmental hygiene also has a broader meaning, beyond strict spore control – this is called the exposome, that is, the many thousands of environmental influences to which you are exposed day after day, and which subtly shape your microbiome. A few simple points of awareness belong here. Drinking water: aim for clean water from a reliable source; adequate fluid is the foundation of recovery, but the quality of the water matters too. Household disinfectants and antibacterial products: targeted cleaning against CDI spores is justified, but everyday, unjustified use of disinfectants – antibacterial soaps, sprays on every surface – also kills off the useful microbes of your own body and your environment, so here too moderation is the right path: where soapy water is enough, do not disinfect. Finally, healthcare exposure: hospital and clinic environments are one of the main sources of CDI – if you are admitted to an institution, feel free to ask for hand hygiene, to mention your previous infection, and to avoid unnecessary antibiotics.

Few people think of it, but the mouth is a microbiome too – and through the so-called oral–gut axis^[G] it is connected to your digestive system. Regular tooth brushing, the use of dental floss and dental check-ups protect not only your teeth but also reduce the burden of oral pathogens, which can spread to the gut. This is a small, easily sustainable habit that supports your whole microbiome health.

The next pillar is lifestyle, which keeps your flora so diverse and resilient that the pathogen has nowhere to re-establish itself. These are the same few habits you built during recovery: a varied, fibre-rich diet, enough sleep, regular exercise and stress management. Together they strengthen colonisation resistance^[G] – that is, your flora's ability to crowd out the pathogen on its own. Here continuity is the goal: it is worth keeping these habits not just until the end of the programme, but beyond it.

Finally, prevention also means knowing your own early signs, and not being ashamed to ask for help in time. If symptoms were ever to reappear, the vigilance you learned earlier – attention measured against your logged baseline – and prompt medical contact are the most effective. Prevention is therefore not a single rule, but an attitude: the awareness with which you protect the balance you worked for over ninety days.

🍽️ Eating during these days

On the eating side, the theme of prevention means keeping the gut flora so diverse and resilient that the pathogen has nowhere to re-establish itself. Alongside antibiotic awareness and hygiene, a varied, fibre-rich diet is the third, quiet pillar of prevention – it is what sustains colonisation resistance over the long term. The concrete eating task for the three days is in harmony with the daily tasks: keep up conscious fluid replacement, choose 2–3 dietary habits to carry on lastingly, and each day include the plant of the day in at least one meal.

For these days (76–78), the Plant Calendar (Appendix F) brings the sources chicory / chicory coffee (76), black garlic (77) and prunes (78). Chicory is one of the richest natural sources of inulin – a strongly fermentable prebiotic^[G] fibre from which the useful gut bacteria make short-chain fatty acids^[G], including butyrate^[G]; black garlic is fermented and rich in polyphenols^[G], and prunes support regularity once the stool is already stable. In the second half of the programme (roughly days 61–90), the goal is precisely to sustain full diversity^[G] and inulin-rich, fermentable sources: a diverse, well-fed flora is more resilient, and this resilience is the biological basis of prevention. Inulin sources can be more gas-forming; introduce them according to your tolerance, and prunes only if your stool is stable.

Why does this matter?

Prevention is holding on to your recovery. The chief trigger of relapse is unnecessary antibiotics, so your most important line of defence is conscious antibiotic use – always with your doctor, who knows your CDI history. Environmental hygiene and sustained lifestyle habits provide a quiet safety net, and lifestyle keeps your flora diverse and resilient. Prevention is not a single rule, but an attitude with which you protect what you worked for over ninety days.

References

[003] Reed AD, Theriot CM. Contribution of Inhibitory Metabolites and Competition for Nutrients to Colonization Resistance against Clostridioides difficile by Commensal Clostridium**. Microorganisms. 2021. Link

This review examines how commensal *Clostridium* species mediate colonization resistance against C. difficile. Commensal *Clostridia* modify primary bile acids into secondary bile acids that suppress C. difficile spore germination and vegetative outgrowth. They additionally produce antimicrobial peptides and short-chain fatty acids that directly inhibit C. difficile and compete for limiting nutrients such as proline, important for C. difficile growth via Stickland fermentation. Loss of commensal *Clostridia* after broad-spectrum antibiotics is a key mechanistic step toward CDI susceptibility. The authors conclude from this that new therapies against CDI are urgently needed; the clinical validation of defined *Clostridium* consortia comes not from this review but from the VE303 phase 2 trial [56].

[005] Kelly C, Fischer M, Allegretti J, LaPlante K, Stewart D, Limketkai B, Stollman N. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. The American journal of gastroenterology. 2021. Link

According to the 2021 ACG guideline, FMT is part of standard care for rCDI; strongly recommended after ≥2 recurrences — American College of Gastroenterology's latest CDI guidelines: FMT strongly recommended after ≥2 CDI recurrences; capsule and colonoscopic administration are equivalent; detailed donor screening and storage protocol; COVID-era updates regarding FMT safety also incorporated.

[012] Imhann F, Bonder MJ, Vich Vila A et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016. Link

Imhann and colleagues' 2016 Gut paper reports that proton pump inhibitor (PPI) use significantly alters the human gut microbiota. Combining three population cohorts (>1800 individuals) with 16S rRNA sequencing, the authors show that PPI users have decreased microbial diversity and consistent shifts in 20% of bacterial taxa: increases in oral-cavity bacteria (Streptococcaceae, Enterococcaceae), Enterobacteriaceae and *Clostridium* difficile, alongside decreases in commensals such as Ruminococcaceae and Bifidobacteriaceae. These shifts mechanistically explain epidemiological associations between PPI use and CDI, enteric infection, hepatic encephalopathy and SIBO. The work supports prudent PPI prescribing and deprescription efforts.

[023] McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC et al. Clinical Practice Guidelines for Clostridium. difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases. 2018. Link

Comprehensive IDSA/SHEA clinical practice guideline on the diagnosis, treatment and prevention of C. difficile infection in adults and children. It defines severity categories (non-severe, severe, fulminant) and characterises fulminant disease by hypotension or shock, ileus or toxic megacolon — findings that require inpatient care, intravenous therapy and surgical consultation. For multiply recurrent infection in which antibiotic therapy has repeatedly failed, faecal microbiota transplantation is recommended. This document provides the international frame to which the book's red flags and hospital-referral signs are aligned.

[036] Chassaing B, Koren O, Goodrich JK, Poole AC, Srinivasan S, Ley RE, Gewirtz AT. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015. Link

Landmark Nature paper showing that two ubiquitous dietary emulsifiers – carboxymethylcellulose (CMC, E466) and polysorbate-80 (P80, E433) – induced low-grade intestinal inflammation even at relatively low concentrations, altered microbiota composition, and produced obesity/metabolic syndrome in wild-type mice. The authors themselves note that the extent of human emulsifier consumption is not tracked, but that, given how widespread emulsifiers are in food production, actual human exposure may exceed the 1.0 percent level used in the experiment. In mice predisposed to colitis, the same compounds triggered overt colonic inflammation. The authors propose emulsifier exposure as a contributor to the post-1950 rise in IBD and metabolic disease. A corrigendum has been issued for the paper (Corrigendum: *Nature* 2016;536(7615):238). This is the central evidence cited in Section 8.3 of this Guide regarding industrial food production as a chronic input into dysbiosis.

[037] Chassaing B, Van de Wiele T, De Bodt J, Marzorati M, Gewirtz AT. Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation. Gut. 2017. Link

Follow-up to Chassaing 2015 extending the findings from mice to a human-microbiota model (the M-SHIME ex vivo system). Both emulsifiers increased the pro-inflammatory potential of the microbiota, demonstrably so through elevated flagellin levels; the composition of the community, however, was altered only by P80, while the effect of CMC operated through microbiota gene expression. The rise in lipopolysaccharide levels occurred only with P80, and at higher doses. When a suspension of the emulsifier-treated microbiota was administered to immunodeficient (RAG−/−) mice, serum IL-6 levels rose significantly. The work confirms that the murine findings translate to human gut ecology and reinforces the argument that dietary reform is a clinical, not an aesthetic, component of the maintenance phase.

[077] Atarashi K, Suda W, Luo C et al. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. Science. 2017. Link

This gnotobiotic study showed that salivary Klebsiella strains, when colonizing the gut, are strong inducers of T helper 1 (TH1) cells. These antibiotic-resistant Klebsiella strains colonize when intestinal microbiota are dysbiotic and elicit severe gut inflammation in genetically susceptible hosts. The findings establish the oral cavity as a reservoir for potential intestinal pathobionts that exacerbate disease such as IBD when ectopically colonizing the gut.

[079] Hajishengallis, G. Periodontitis: from microbial immune subversion to systemic inflammation. Nat Rev Immunol. 2015. Link

This review discusses how dysbiotic oral microbial communities drive periodontitis and inflammatory pathology at local and distant sites. The authors detail microbial immune subversion mechanisms that tip oral homeostasis to disease. Periodontitis emerges as a dysbiotic inflammatory disease with systemic implications, including links to cardiovascular and other chronic diseases. The findings frame periodontitis treatment as a strategy with potential systemic-health benefits.

[085] Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology. 2022. Link

A clinical update provides Best Practice Advice statements for PPI de-prescribing in ambulatory patients. PPIs are among the most-prescribed medications and are increasingly used for indications with uncertain benefit, contributing to polypharmacy and economic burden. PPI use has been increasingly associated with PPI-associated adverse events (PAAEs). The guidance promotes structured de-prescribing strategies to reduce pill burden, real costs and theoretical risks while ensuring patients with appropriate indications continue therapy.

[107] Vanhaecke T, Bretin O, Poirel M, Tap J. **. J Nutr. 2022. Link

Using the American Gut Project database (3,413 and 3,794 faecal samples), the authors examined how drinking water **source** and daily **intake** relate to gut and oral microbiota composition, adjusted for anthropometric, dietary and lifestyle factors. Drinking water source ranked among the key factors explaining gut microbiota variation, and both source and amount were associated with distinct microbiota signatures — including differences in the relative abundance of Campylobacter. Important: this is a cross-sectional association, not causal evidence, and not in an FMT population.

[154] Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis. JAMA Intern Med. 2017. Link

Systematic review and meta-analysis of whether gastric acid suppression (mainly PPIs, and H2 blockers) is associated with the risk of **recurrent** *Clostridioides difficile* infection. Five databases were searched from 1995–2015; case-control, cohort and clinical studies were included in which CDI patients did or did not receive gastric acid suppression and recurrence was assessed. Gastric acid suppression was associated with significantly higher odds of recurrent CDI (pooled OR about 1.5). This entry is the source for the III.11 claim that long-term PPI use carries an elevated risk of recurrent CDI. **LIMITATION:** a meta-analysis of observational studies — association, not causation; the authors themselves caution about residual confounding (PPI users are often sicker/older), so unsupervised discontinuation is not warranted, only clinical review.

[155] Langdon A, Schwartz DJ, Bulow C, Sun X, Hink T, Reske KA, Dubberke ER, Dantas G. Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study. Genome Med. 2021. Link

Secondary analysis of an open-label clinical trial (PUNCH CD): faecal samples from 29 recurrent-CDI patients were analysed before and up to six months after administration of the microbiota-based product RBX2660, by 16S sequencing, whole-metagenome shotgun sequencing (resistome content) and selective culture. Successful prevention of CDI recurrence correlated with taxonomic convergence of patient microbiota toward the donor; RBX2660 **dramatically reduced the abundance of antibiotic-resistant Enterobacteriaceae** in the 2 months after administration, and **faecal antibiotic resistance gene (resistome) carriage decreased in direct relationship to the degree to which the donor microbiota engrafted**. This entry is the source for the IV.1 claim that donor-microbiota engraftment and resistome restoration dynamics are linked. **LIMITATION:** open-label, small sample (n=29), and the product studied is **RBX2660** (not DiffBiome) — the mechanism concerns rCDI microbiota therapy, not product-specific evidence.

[667] Sanidad KZ, Xiao H, Zhang G, et al. Triclosan has a robust, yet reversible impact on human gut microbial composition in vitro. . 2020. Link

In an in vitro human gut microbiome model, triclosan robustly altered the microbial community: it reduced population size, diversity and metabolite production, selectively suppressing certain commensal taxa. The effect was largely reversible after a two-week recovery period. The study provides direct mechanistic evidence for triclosan's microbiota-disrupting effect; triclosan's antibiotic-resistance-selecting potential is supported by separate exposure (mouse and environmental) studies.